Abstract: A mixture of octanols, nonanols and decanols is useful for the preparation of alkoxylates, which alkoxylates may be used as surfactants, which surfactants have surprisingly good biodegradability.

Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Abstract: An epoxy group-containing a fluorene compound has a methallyl group at the end thereof and is represented by the following general formula (1): wherein R represents a hydrogen atom or a methyl group. The compound gives a compound excellent in regioselectivity at the time of hydrosilylation with a Si—H containing organosilicon compound, with a less formed amount of an internally added ? adduct, as compared with the conventionally known fluorene compound having an allyl group, so that heat resistance of the resulting organosilicon compound is expected to be improved whereby it is a useful compound.

Abstract: A composition comprising linked segments of: (a) a polyhydroxy segment derived from a compound independently selected an acyclic polyhydric alcohol having 4 to 6 carbon atoms and 4 to 6 reactive hydroxyl groups; a cyclic polyhydric alcohol having 4 to 6 carbon atoms and 4 to 6 reactive hydroxyl groups, a poly(hydroxyethyl) polyethyleneamine having 4 to 6 reactive hydroxyl groups and combinations thereof; (b) polyoxyalkylene segments wherein each hydroxyl group of the polyhydroxyl segment is linked to a polyoxyalkylene segment; (d) and aliphatic end segments or aromatic end segments, each end segment having 6 to 32 carbon atoms and a hydroxyl reactive group, wherein the mole ratio of the polyoxyalkylene segment to the polyhydroxy segment is at least 4:1 and the mole ratio of the aliphatic or aromatic end segment to the polyhydroxy segment is at least 0.25:1.

Abstract: The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C.

Abstract: The present invention relates to novel heterocyclic alkanol derivatives, to processes for these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogs. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.

Abstract: The present invention relates to substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkynyloxy-ethyl}-1H-[1,2,4]triazole compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.

Abstract: The present invention relates to substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkoxy-3-methyl-butyl}-1H-[1,2,4]triazole compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.

Abstract: The present invention relates to substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkoxy-2-cyclyl-ethyl}-1H-[1,2,4]triazole compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.

Abstract: A composition is provided that, when utilized in combination with warfarin, greatly improves the anticoagulant effects of warfarin in mammalian subjects. The composition is a compound having a naphthohydroquinone ring system substantially similar to the ring system of the reduced form of vitamin K1 and has the general formula: where R1 and R4 are hydrogen or acyl, R2 is a saturated or unsaturated alkyl group with up to 6 carbons, and R3 is a saturated or unsaturated alkyl group with up to 20 carbons, or R2 and R3 are part of a cyclic or polycyclic ring system.

Abstract: The present invention relates to substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)phenyl]-2-ethoxy-ethyl}-1H-[1,2,4]triazole compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.

Abstract: The present invention relates to substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound.

Abstract: The present invention relates to a novel enantioselective method of preparing (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-5 methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide.

Abstract: The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.

Abstract: The present invention relates to phenylalkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound.

Abstract: The present invention relates to alkyl- and aryl-substituted 2-[2-chloro-4-(dihalo-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.

Abstract: Disclosed is a liquid crystal photo-alignment agent and a liquid crystal photo-alignment film manufactured using the same. The liquid crystal photo-alignment agent includes an epoxy compound represented by Chemical Formula 1, and a polymer including a polyamic acid, a polyimide, or a mixture thereof.

Abstract: The present invention relates to the use of alkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof for combating harmful fungi and seed coated with at least one such compound. The invention also relates to novel alkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound.

Abstract: Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases and disorders.

Abstract: Reduced color epoxidized fatty acid esters are provided which may be used as primary plasticizers for PVC, in replacement of phthalate plasticizers. The reduced color epoxidized fatty acid esters are prepared from natural fats or oils by transesterification and interesterification processes, whereby through the use of borohydride, materials having Pt-Co colors according to ASTM D1209 on the order of 50 and lower are possible.

Abstract: A process for the preparation of an organic reactive intermediate that contains a combination of epoxy groups, hydroxy groups and unsaturated groups wherein the process can be utilized to control the amounts of each of the functional groups in the final product. The reactive intermediates are prepared from natural triglyceride plant and animal oils containing unsaturation.

Abstract: The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C. to produce dibromogalactitol; (2) reacting the dibromogalactitol with potassium carbonate in t-butanol to produce dianhydrogalactitol; and (3) purifying the dianhydrogalactitol using a slurry of ethyl ether to produce purified dianhydrogalactitol. Another method produces dianhydrogalactitol from dulcitol; this method comprises: (1) reacting dulcitol with a reactant to convert the 1,6-hydroxy groups of dulcitol to an effective leaving group to generate an intermediate; and (2) reacting the intermediate with an inorganic weak base to produce dianhydrogalactitol through an intramolecular SN2 reaction. Other methods for the synthesis of dianhydrogalactitol from dulcitol are described.

Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.

Abstract: A compound is disclosed. The compound has a general structure: wherein R1, R2, and R3 are each independently selected from the group consisting of hydrogen, substituted saturated hydrocarbons, non-substituted saturated hydrocarbons, substituted unsaturated hydrocarbons, and non-substituted unsaturated hydrocarbons; wherein E and D are each independently selected from the group consisting of CH2, O, S, and NH; and wherein a, b, x, y, and z are each independently any whole number between 0 and 45, inclusive, wherein the sum of a and b is less than 45 or equal to 45 and wherein the sum of x, y, and z is less than 45 or equal to 45.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.

Abstract: A graphene oxide used as a raw material of a conductive additive for forming an active material layer with high electron conductivity with a small amount of a conductive additive is provided. A positive electrode for a nonaqueous secondary battery using the graphene oxide as a conductive additive is provided. The graphene oxide is used as a raw material of a conductive additive in a positive electrode for a nonaqueous secondary battery and, in the graphene oxide, the weight ratio of oxygen to carbon is greater than or equal to 0.405.

Abstract: An ink jet penetrant contains a compound represented by general formula (1), and this compound is obtained by a block polymerization process for sequentially polymerizing an alcohol represented by general formula (2) with propylene oxide and then with ethylene oxide. The amount of this alcohol in the penetrant is 1% by mass or less.

Abstract: Nonpolymeric compounds, compositions, and methods for forming microelectronic structures, and the structures formed therefrom are provided. The nonpolymeric compounds are ring-opened, epoxide-adamantane derivatives that comprise at least two epoxy moieties and at least one adamantyl group, along with at least one chemical modification group, such as a chromophore, bonded to a respective epoxy moiety. Anti-reflective and/or planarization compositions can be formed using these compounds and used in lithographic processes, including fabrication of microelectronic structures.

Abstract: The present invention relates to an inhibitor for tobacco axillary bud growth, the inhibitor comprising, as an active ingredient, one or more kinds of very-long chain fatty acid synthesis inhibitors such as a chloroacetamide-based herbicide, fentrazamide, cafenstrole or indanofan; an inhibitor for tobacco axillary bud growth, the inhibitor comprising the aforesaid very-long chain fatty acid synthesis inhibitor together with clorthal-dimethyl or an aliphatic alcohol having 6 to 20 carbon atoms; and a method for inhibiting tobacco axillary bud growth which comprises applying the inhibitor for tobacco axillary bud growth. The inhibitor for tobacco axillary bud growth of the present invention shows sustained drug efficacy at a low concentration, induces neither chemical injury nor disease, and can contribute to the improvement in labor productivity.

Abstract: An automotive engine oil and/or fuel comprising a base stock and an organic polymeric friction reducing additive is claimed. A method of reducing friction in an automotive engine oil and/or fuel by the addition of the organic polymeric friction reducing additive to the base stock is also claimed.

Abstract: The purpose of the invention is to provide a polymerizable liquid crystal compound that has a liquid crystal phase with a wide temperature range, has an excellent compatibility with another polymerizable liquid crystal compound, has an excellent solubility in organic solvent and is polymerizable in air by heat or light. Means for Solving the Subject A polymerizable liquid crystal compound represented by formula (1) wherein A1 and A2 are a ring such as 1,4-cyclohexylene and 1,4-phenylene; Z1 to Z3 are a bonding group such as a single bond and —O—, m is an integer of 1 to 5; Q1 and/or Q2 are —O(C2H4O)n1(C3H6O)n2— or —O(C3H6O)n2(C2H4O)n1—, where n1 and n2 are integer of 0 to 5 and the sum of n1 and n2 is 2 to 5; one of Q1 and Q2 may be alkylene; P1 and P2 are a polymerizable group represented by any one of formula (2-1) to formula (2-3) and R is hydrogen, halogen or alkylene having 1 to 5 carbons.

Abstract: The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.

Abstract: The present invention provides a diaryl sulfone compound represented by Formula (1) below: wherein R1 to R4 and R1? to R4? are the same or different; each represents hydrogen, C1-4 alkyl, or halogen; and R5 is (thio)glycidyl, acryloyl, or the like; and a method for producing the same. According to the present invention, a novel compound useful as a monomer for producing synthetic resin having a high refractive index and excellent transparency for optical materials can be efficiently produced with a simple production process, using an inexpensive material as a starting material.

Abstract: To provide shrinkage reducing agents which render excellent shrinkage reducing effect and frost-thaw resistance to cement compositions such as mortar and concrete without entraining excessive air, and exhibit excellent solution stability. The shrinkage reducing agent comprises a (poly)alkylene compound having an unsaturated bond represented by the formula (1): R2O—R1—O-(A1O)n—R3??(1) -(A2O)m—R4??(2) (wherein R1 is a C2-10 hydrocarbon group having an unsaturated bond; R2 is hydrogen or the formula (2); R3 and R4 are each independently hydrogen or a C1-8 alkyl group; A1O and A2O are one or more kinds of C2-4 oxyalkylene groups; and n and m are mean addition numbers of moles of A1O and A2O, respectively, and 1 to 20).

Abstract: To provide an azole derivative which is contained as an active ingredient in an agro-horticultural agent having an excellent controlling effect on diseases. An azole derivative according to the invention is represented by Formula (I), wherein R1 and R2 are same or different, and each denotes a substituted C3-C6 cycloalkyl group or a C1-C4 alkyl group substituted with the substituted C3-C6 cycloalkyl group; and A denotes a nitrogen atom or a methyne group.

Abstract: A process for the preparation of an organic reactive intermediate that contains a combination of epoxy groups, hydroxy groups and unsaturated groups wherein the process can be utilized to control the amounts of each of the functional groups in the final product. The reactive intermediates are prepared from natural triglyceride plant and animal oils containing unsaturation.

Abstract: To provide shrinkage reducing agents which render excellent shrinkage reducing effect and frost-thaw resistance to cement compositions such as mortar and concrete without entraining excessive air, and exhibit excellent solution stability. The shrinkage reducing agent comprises a (poly)alkylene compound having an unsaturated bond represented by the formula (1): R2O—R1—O-(A1O)n—R3??(1) -(A2O)m—R4??(2) (wherein R1 is a C2-10 hydrocarbon group having an unsaturated bond; R2 is hydrogen or the formula (2); R3 and R4 are each independently hydrogen or a C1-8 alkyl group; A1O and A2O are one or more kinds of C2-4 oxyalkylene groups; and n and m are mean addition numbers of moles of A1O and A2O, respectively, and 1 to 20).

Abstract: A method of synthesizing a functionalized polymer represented by the structural formula (I) comprising a step of reacting a polymer represented by structural formula (II) with a compound Nu1-M to nucleophilically substitute moiety X1 with moiety Nu1. Values and preferred values of the variables in formulas (I) and (II) are defined herein.

Abstract: In some embodiments, without limitation, a hydrophobic photoresist material and a method of making the photoresist material are provided. The photoresist material is derived by creating a high resolution insoluble, or more soluble, polymer structure as a result of a controlled chemical reaction with a functionalized perfluoropolyether. Also provided are methods of coating an inkjet printhead surface and processing the coated inkjet printhead surface.

Abstract: Adamantane derivatives are provided including a phenolic hydroxyl group-containing adamantane derivative, a glycidyloxy group-containing adamantane derivative, and an adamantyl group-containing epoxy modified acrylate, which exhibit excellent transparency, light resistance, and heat resistance properties. Also provided are resin compositions containing the adamantane derivatives. Further provided are corresponding methods for producing the adamantane derivatives, as well as the resin compositions containing the same.

Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.

Abstract: A process for the preparation of an organic reactive intermediate that contains a combination of epoxy groups, hydroxy groups and unsaturated groups wherein the process can be utilized to control the amounts of each of the functional groups in the final product. The reactive intermediates are prepared from natural triglyceride plant and animal oils containing unsaturation.

Abstract: Process for the continuous preparation of N-ethyl-2-pyrrolidone (NEP) by reacting gamma-butyrolactone (GBL) with monoethylamine (MEA) in the liquid phase, wherein GBL and MEA are used in a molar ratio in the range from 1:1.08 to 1:2 an the reaction is carried out at a temperature in the range from 320 to 420° C. and an absolute pressure in the range from 70 to 120 bar.

Abstract: Cleaning compositions are described comprising mid-range alkoxylate surfactants or blends of alkoxylate surfactants, and their use as cleaners for triglycerides and cross-linked triglycerides, formula stabilization agents, agents for ultra-concentrated cleaning formulations, pre-wash spotters, detergents, agricultural adjuvants, hard surface cleaning, and emulsifiers.

Abstract: Provided is a polymer polyol which has solved problems, such as clogging in a discharge head and insufficient hardness of a resulting polyurethane foam, occurring in the production of a polyurethane foam by mechanical foaming using a conventional polymer polyol as a raw material. The present invention is a polymer polyol (A) in which polymer fine particles (JR) having an ethylenically unsaturated compound (E) as a constituent unit are contained in a polyol (PL), wherein the (PL) comprises a polyol (a) with which the average number x of moles of ethylene oxide added per active hydrogen atom and the primary hydroxidation ratio y of terminal hydroxyl groups satisfy a specific relationship, and the volume average particle diameter (R) of the (JR) is from 0.1 to 1.5 ?m.

Abstract: The present invention describes the method of making anionic ether sulfate surfactants by alkoxylation of a GA using PO and/or EO followed by a sulfation reaction. The GA of the present invention is made by a facile and inexpensive method that involves high temperature base catalyzed dimerization of a linear alcohol. The ether sulfate surfactants of the present invention find uses in EOR applications where it is used for solubilization and mobilization of oil and for environmental cleanup.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.